The first EU GMP standard phage factory opening in Georgia
The Georgian biopharmaceutical company BioChimPharm (BCP) has completed the process of modernization of its historic Bacteriophage (Phage) manufacturing factory. As a result, BioChimPharm reequipped the Phage Factory in compliance with the EU GMP (Good Manufacturing Practice) guidelines, an accepted standard in the European Union and the Company plans applying for GMP certification within the following months.
About Us
“The production of phage preparations and the phage therapy are still a novelty for most of the countries around the world. Millions of people still do not have access to phages, leaving patients vulnerable towards antibiotic-resistant infections. With this project, the Company is increasing its production capacity and export area, thus making phages available for millions of patients across the globe.
The modernization of the manufacturing plant, high-tech infrastructure and production lines enables the Company to scale-up its production in compliance with internationally recognized manufacturing standards, to become more effective in fight against the resistant infections and overcome the global threat of antibiotic resistance.” – said Rati Golijashvil, the general manager of BioChimPharm.
Modernization
The Company has completed a 2-year investment project worth GEL 17.5 million (€ 6,000,000) with the support of the EU, the EBRD and the Ministry of Economy and Sustainable Development of Georgia.
The newly modernized plant of BioChimPharm is located in Tbilisi, in the historic bacteriophage institute and represents the first enterprise producing sterile liquid dosage forms in the South Caucasus, covering the full production cycle, including the production of active pharmaceutical ingredients (APIs, substance), as well as primary and secondary packaging of medicines.
